BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring

November 10, 2016 11:44 AM EST
Get Alerts MACK Hot Sheet
Price: $5.61 +2.37%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade MACK Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BTIG affirms Merrimack Pharma (Nasdaq: MACK) at Neutral following Q3 results and announced restructuring.

Analyst Ling Wang commented, Q16 ONIVYDE net revenues of $14.5M slightly missed consensus ($16.6M) and our estimate ($16.7M). It ended 3Q16 with cash & equivalents of $48.5M. Management provided updated 2016 and 2017 expense guidance and guided cash runway into 2018. Recall, MACK recently announced a major corporate restructuring; it is now in the middle of a firmwide strategic review of its pipelines (expects to be completed by YE16). We view the effort to prioritize projects and contain expenses as positive, but we remain on the sidelines and wait for further clarity on the key pipeline programs going forward.

For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

BTIG

Add Your Comment